Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L01EX09	OFEV	B	Nintedanib - 100mg	100mg	Capsule, soft	104,970,726 L.L
L04AA32	OTEZLA	B	Apremilast - 4x10mg- 4x20mg- 19x30mg		Tablet, film coated	34,751,325 L.L
L01EX09	OFEV	B	Nintedanib - 150mg	150mg	Capsule, soft	209,943,871 L.L
L04AA32	OTEZLA	B	Apremilast - 30mg	30mg	Tablet, film coated	49,829,454 L.L
L04AA37	OLUMIANT	B	Baricitinib - 2mg	2mg	Tablet, film coated	68,053,864 L.L
L04AA37	OLUMIANT	B	Baricitinib - 4mg	4mg	Tablet, film coated	68,053,864 L.L
S01AE01	OFLOX	B	Ofloxacin - 3mg/ml	0.30%	Drops solution	366,869 L.L
S01AE01	OFLOX	B	Ofloxacin - 0.3%	0.30%	Drops solution	366,869 L.L
J01XA05	ORBACTIV	B	Oritavancin (diphosphate) - 400mg	400mg	Injectable powder for concentrate for solution + solvent	157,078,205 L.L
A03AX13	OVOL	B	Simethicone - 40mg/ml	40mg/ml	Drops	233,829 L.L
L01EX09	OFEV	B	Nintedanib - 150mg	150mg	Capsule, soft	L.L
A03AX13	OVOL FOR GAZ	B	Simethicone - 180mg	180mg	Capsule, liquid gel	241,892 L.L
C02KX04	OPSUMIT	B	Macitentan - 10mg	10mg	Tablet, film coated	L.L
S01BA01	OZURDEX	B	Dexamethasone - 700mcg	700mcg	Implant	80,696,540 L.L
H01CC01	ORGALUTRAN	B	Ganirelix - 0.25mg/0.5ml	0.25mg/0.5ml	Injectable solution	2,383,977 L.L
S01BA01	OZURDEX	B	Dexamethasone - 700mcg	700mcg	Implant	80,696,540 L.L
H01CC01	ORGALUTRAN	B	Ganirelix - 0.25mg/0.5ml	0.25mg/0.5ml	Injectable solution	2,383,977 L.L
N05AG02	ORAP FORTE	B	Pimozide - 4mg	4mg	Tablet	329,241 L.L
B05BA10	OLIMEL N9E	B	Glucose solution - 27.5%, Amino acids solution - 14.2%, Lipid emulsion - 20%, Sodium - 70mmol/2l, Potassium - 60mmol/2l, Magnesium - 8mmol/2l, Calcium - 7mmol/2l, Phosphate - 30mmol/2l, Acetate - 107mmol/2l, Chloride - 90mmol/2l, Azote - 18g/2l		Injectable emulsion	5,496,316 L.L
J01DD15	OMNICEF	B	Cefdinir - 125mg/5ml	125mg/5ml	Powder for suspension	1,189,301 L.L
J01DD15	OMNICEF	B	Cefdinir - 125mg/5ml	125mg/5ml	Powder for suspension	2,025,171 L.L
J01DD15	OMNICEF	B	Cefdinir - 125mg/5ml	125mg/5ml	Powder for suspension	2,025,171 L.L
J01DD15	OMNICEF	B	Cefdinir - 125mg/5ml	125mg/5ml	Powder for suspension	1,189,301 L.L
G03CA03	OESTRODOSE	B	Estradiol (17 bêta estradiol anhydre) - 0.06%	0.06%	Gel	642,357 L.L
J01DD15	OMNICEF	B	Cefdinir - 300mg	300mg	Capsule	2,238,842 L.L
J01DD15	OMNICEF 300	B	Cefdinir - 300mg	300mg	Capsule	2,238,842 L.L
J01DD15	OMNICEF	B	Cefdinir - 250mg/5ml	250mg/5ml	Powder for suspension	3,670,034 L.L
A05AA04	OCALIVA	B	Obeticholic acid - 10mg	10mg	Tablet, film coated	224,503,943 L.L
A05AA04	OCALIVA	B	Obeticholic acid - 5mg	5mg	Tablet, film coated	224,503,943 L.L
S02DA01	OTIPAX	B	Lidocaine HCl - 1g/100g, Phenazone - 4g/100g		Drops	236,516 L.L

...